<DOC>
	<DOCNO>NCT00230087</DOCNO>
	<brief_summary>The purpose study find whether lower amount iron body result less resistance insulin improve liver function patient type 2 diabetes mellitus non-alcoholic fatty liver disease . This may result good diabetes control and/or decrease amount liver fat .</brief_summary>
	<brief_title>Iron Depletion Therapy Type 2 DM NAFLD</brief_title>
	<detailed_description>Nonalcoholic fatty liver disease ( NAFLD ) common liver disease United States . NAFLD lead severe liver disease patient . Patients NAFLD develop resistance normal action insulin . Insulin important processing sugar fat increase resistance insulin lead fat liver . There correlation amount iron person 's body ability insulin work properly . Several small study suggest removal iron may improve diabetes NAFLD lower insulin resistance . The goal pilot study determine effect iron depletion insulin sensitivity patient type 2 diabetes mellitus non-alcoholic fatty liver disease . This study perform ancillary P &amp; F study NASH CRN ; participant recruit NASH CRN Database Study . Secondary outcome measure include effect iron depletion hepatic necroinflammation , marker oxidative stress intrahepatic fat content . Insulin resistance directly measure use two-step hyperinsulinemic euglycemic clamp procedure , iron depletion phlebotomy . Oral glucose tolerance test also perform order evaluate efficacy use indirect , less cumbersome , HOMA model derive value insulin resistance patient cohort . This study advance understanding role body iron store pathophysiology type 2 diabetes mellitus non-alcoholic fatty liver disease . If iron depletion result improve insulin sensitivity , reduce hepatic necroinflammation and/or intrahepatic fat content , large scale , randomize , control trial iron depletion patient type 2 diabetes mellitus non-alcoholic fatty liver disease plan .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>Inclusion Criteria Histological evidence NAFLD enrollment NASH CRN Database Study Type 2 DM treat diet stable dose noninsulin sensitize oral hypoglycemic agent &gt; 3 mo . Hemoglobin HbA1c level ≤ 8 % Serum ALT level ≥1.3 x ULN Between 1865 year age Exclusion Criteria Hereditary hemochromatosis hepatic iron overload define follow : 2+ iron hepatic iron stain Hepatic Iron Index ≥ 1.9 C282Y homozygous C282Y/H63D compound heterozygous HFE genotype Use insulin thiazolidinediones treatment diabetes Use antiNASH drug ( thiazolidinediones , vitamin E , UDCA , SAMe , betaine , milk thistle , gemfibrozil , antiTNF therapy , probiotic ) Serum ferritin &lt; 50μg/L Serum transferriniron saturation &lt; 10 % Hemoglobin &lt; 10 mg/L Hematocrit &lt; 38 % Voluntary blood donation therapeutic phlebotomy within previous twelve month ( except routine lab test ) Pregnant lactate woman Prior history coronary artery disease , myocardial infarction , exertional dyspnea chronic chest pain rest . Evidence myocardial infarction determine ECG</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>diabetes</keyword>
	<keyword>nafld</keyword>
	<keyword>nash</keyword>
	<keyword>phlebotomy</keyword>
</DOC>